Orphan drug Ilaris receives conditional pass for reimb again
By Lee, Hye-Kyung | translator Kim, Jung-Ju
24.04.04 17:38:01
가나다라
0
Again caught by the condition that requires post-marketing evidence submission…whether Novartis will accept the condition remains key to Ilaris’s reimbursement
Redeliberation conducted after the company filed an objection to February's deliberation results…but received the same decision
Although the government restarted reimbursement discussions for Novartis Korea's orphan drug Ilaris Inj (canakinumab) after 2 months, the results were the same.
According to the "Results of the 4th 2024 Drug Reimbursement Review Committee Deliberations," which was released on the 4th by the Health Insurance Review and Assessment Service, Ilaris was deemed adequate for reimbursement for the following indications: ▲Cryopyrin-Associated Periodic Syndromes (CAPS), Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), ▲Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD), ▲Familial Mediterranean Fever (FMF), and ▲ Systemic Juvenile Idiopathic Arthritis (SJIA).
Lee, Hye-Kyung(hgrace7@dailypharm.com)
If you want to see the full article, please JOIN US (click)